Biotinylated Human TL1A / TNFSF15 Protein, His,Avitag™
分子别名（Synonym）
TL1A, VEGI, TNFSF15
表达区间及表达系统（Source）
Biotinylated Human TL1A Protein, His,Avitag (TLA-H52Q1) is expressed from human 293 cells (HEK293). It contains AA Leu 72- Leu 251 (Accession # O95150-1).
Predicted N-terminus: His
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 24.1 kDa. The protein migrates as 28-32 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>90% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, 0.5 M Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
肿瘤坏死因子样细胞因子1A（TL1A）及其受体死亡受体3（DR3）、诱骗受体3（DcR3）分别隶属于肿瘤坏死因子超家族（TNFSF15）和肿瘤坏死因子受体超家族（TNFRSF25/TNFRSF6B）。当抗原呈递细胞（APC）来源的TL1A与淋巴细胞表面DR3结合时，可为活化淋巴细胞提供共刺激信号；DR3信号不仅增强效应淋巴细胞的增殖活性与细胞因子分泌，同时显著抑制调节性T细胞（Treg）的发育及免疫抑制功能。而DcR3作为关键负调控因子，通过拮抗TL1A/DR3复合物功能，有效抑制T细胞活化并下调促炎细胞因子（如TNF-α、IFN-γ、IL-17）分泌。TL1A-DR3-DcR3由此构成精密的三元免疫调节系统，通过双向调控效应T细胞应答强度、Treg功能状态及炎症反应平衡，主动干预免疫应答全局调控网络。
关键字： TL1A;TL1A蛋白;TL1A重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。